Inactive Instrument

Vansen Pharma Inc.

VNSN

US92209Y1010

Okana Ventures Inc. announced that it has received $1.45 million in funding.

July 30, 2013 at 12:00 am EDT

Okana Ventures Inc. announced a private placement of 3,152,174 common shares at $0.46 per share for gross proceeds of $1,450,000 on July 30, 2013.

On July 30, 2013, Okana Ventures Inc. closed the transaction.

Latest news about Vansen Pharma Inc.

Vansen Pharma Inc. will Change its Ticker to VNSN.E from VNSN	14-04-21	CI
Vansen Pharma Inc. acquired Canadian Health Empire and 6708595 CANADA INC. from Kazem Agharazi for CAD 0.47 million.	14-03-17	CI
Vansen Pharma Inc. Appoints Ali Moghaddam to its Board of Advisors	14-03-06	CI
Vansen Pharma Inc. Announces Management Changes	14-03-03	CI
Vansen Pharma Inc has Changed its Ticker to OKNVD from VNSN	13-09-30	CI
Vansen Pharma Inc. will Change its Ticker to VNSN from OKNV.D	13-09-30	CI
Okana Ventures Inc. has Changed its Name to Vansen Pharma Inc	13-08-30	CI
Okana Ventures Inc. acquired Factive product from Merus Labs International Inc. for $3.4 million.	13-08-25	CI
Okana Ventures Inc. Announces Management Changes	13-08-08	CI
Okana Ventures Inc. acquired right, title and interest to certain Spectracef® and Cefditoren Pivoxil products from Vansen Pharma Inc. for $13.6 million.	13-08-07	CI
Okana Ventures Inc. announced that it has received $1.45 million in funding.	13-07-30	CI
Okana Ventures Inc. Auditor Raises 'Going Concern' Doubt	13-04-12	CI

Chart Vansen Pharma Inc.

Duration

Period

More charts

Company Profile

Vansen Pharma Inc., formerly Okana Ventures, Inc., is an integrated healthcare sales and marketing organization focused on acquiring specialty pharmaceutical products and stable cash flow healthcare businesses. The Company's products include Factive, Spectracef, Cefditoren Pivoxil and Prednisolone 25. The Company acquired the product rights for Factive (Gemifloxacin Mesylate) tablets from Merus Labs International Inc. Factive is a fluoroquinolone antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB) and community-acquired pneumonia of mild to moderate severity (CAP).

Sector

Gold

More about the company

Sector Gold Mining

	1st Jan change	Capi.
NEWMONT CORPORATION	+3.24%	49.27B
AGNICO EAGLE MINES LIMITED	+19.45%	32.63B
BARRICK GOLD CORPORATION	-2.42%	29.96B
WHEATON PRECIOUS METALS CORP.	+12.88%	24.43B
NORTHERN STAR RESOURCES LIMITED	+10.62%	11.31B
ANGLOGOLD ASHANTI PLC	+27.61%	9.95B
POLYUS	-.--%	8.61B
KINROSS GOLD CORPORATION	+14.84%	8.27B
ROYAL GOLD, INC.	+2.99%	8.19B

Gold Mining